OMEGA THERAPEUTICS INC (OMGA) Stock Price & Overview
NASDAQ:OMGA • US68217N1054
The current stock price of OMGA is 0.1426 USD. Today OMGA is down by -10.82%. In the past month the price decreased by -71.98%. In the past year, price decreased by -96.68%.
OMGA Key Statistics
- Market Cap
- 7.896M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.33
- Dividend Yield
- N/A
OMGA Stock Performance
OMGA Stock Chart
OMGA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to OMGA. When comparing the yearly performance of all stocks, OMGA is a bad performer in the overall market: 99.58% of all stocks are doing better.
OMGA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OMGA. OMGA has a bad profitability rating. Also its financial health evaluation is rather negative.
OMGA Earnings
On March 6, 2025 OMGA reported an EPS of -0.3 and a revenue of 2.61M. The company missed EPS expectations (-6.31% surprise) and beat revenue expectations (106.48% surprise).
OMGA Forecast & Estimates
7 analysts have analysed OMGA and the average price target is 13.26 USD. This implies a price increase of 9198.74% is expected in the next year compared to the current price of 0.1426.
For the next year, analysts expect an EPS growth of 34.35% and a revenue growth 233.18% for OMGA
OMGA Groups
Sector & Classification
OMGA Financial Highlights
Over the last trailing twelve months OMGA reported a non-GAAP Earnings per Share(EPS) of -1.33. The EPS increased by 36.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -47.86% | ||
| ROE | -633.21% | ||
| Debt/Equity | 1 |
OMGA Ownership
OMGA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.3 | 402.17B | ||
| AMGN | AMGEN INC | 16.45 | 203.213B | ||
| GILD | GILEAD SCIENCES INC | 16.81 | 182.029B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.75 | 117.075B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.51 | 82.631B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.21 | 42.915B | ||
| INSM | INSMED INC | N/A | 30.852B | ||
| NTRA | NATERA INC | N/A | 29.086B | ||
| BIIB | BIOGEN INC | 11.72 | 27.626B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.94 | 23.193B | ||
| MRNA | MODERNA INC | N/A | 22.014B | ||
| EXAS | EXACT SCIENCES CORP | 340.08 | 19.797B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.775B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OMGA
Company Profile
Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of DNA-sequence-targeting and mRNA-encoded therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 93 full-time employees. The company went IPO on 2021-07-30. The Company’s OMEGA platform has enabled it to identify and validate various DNA-sequence-based epigenomic, zip codes, associated with individual regulatory elements within Insulated Genomic Domains (IGDs). The firm designs and engineers its mRNA therapeutics, called epigenomic controllers, or ECs, to target EpiZips for precision epigenomic control. Its pipeline consists of programs that span oncology, regenerative medicine, and multigenic diseases including immunologic and cardiometabolic conditions. The Company’s precision epigenomic control delivered by the OMEGA platform has therapeutic applicability and transformational potential, spanning across oncology, multigenic diseases including immunologic and cardiometabolic conditions, and regenerative medicine.
Company Info
IPO: 2021-07-30
OMEGA THERAPEUTICS INC
140 First Street, Suite 501
Cambridge MASSACHUSETTS US
CEO: Mahesh Karande
Employees: 94
Phone: 16179494360
OMEGA THERAPEUTICS INC / OMGA FAQ
What does OMEGA THERAPEUTICS INC do?
Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of DNA-sequence-targeting and mRNA-encoded therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 93 full-time employees. The company went IPO on 2021-07-30. The Company’s OMEGA platform has enabled it to identify and validate various DNA-sequence-based epigenomic, zip codes, associated with individual regulatory elements within Insulated Genomic Domains (IGDs). The firm designs and engineers its mRNA therapeutics, called epigenomic controllers, or ECs, to target EpiZips for precision epigenomic control. Its pipeline consists of programs that span oncology, regenerative medicine, and multigenic diseases including immunologic and cardiometabolic conditions. The Company’s precision epigenomic control delivered by the OMEGA platform has therapeutic applicability and transformational potential, spanning across oncology, multigenic diseases including immunologic and cardiometabolic conditions, and regenerative medicine.
What is the current price of OMGA stock?
The current stock price of OMGA is 0.1426 USD. The price decreased by -10.82% in the last trading session.
Does OMGA stock pay dividends?
OMGA does not pay a dividend.
What is the ChartMill technical and fundamental rating of OMGA stock?
OMGA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists OMGA stock?
OMGA stock is listed on the Nasdaq exchange.
What is the market capitalization of OMGA stock?
OMEGA THERAPEUTICS INC (OMGA) has a market capitalization of 7.90M USD. This makes OMGA a Nano Cap stock.